300636 Jiangxi Synergy Pharmaceutical
- 9.82
- -0.17-1.70%
Jiangxi Synergy Pharmaceutical News
Jiangxi Synergy Pharmaceutical (300636.SZ): The active pharmaceutical ingredient of the company has been approved by CDE.
On June 7, Gelunhui reported that Jiangxi Synergy Pharmaceutical (300636.SZ) learned from the National Medical Products Administration of China's Center for Drug Evaluation (CDE) 'Registration Information for Drug Raw and Auxiliary Materials Platform' that the 'Empagliflozin' active pharmaceutical ingredient submitted by the company was approved by the CDE. Empagliflozin is used to treat type 2 diabetes.
Tonghe Pharmaceutical (300636.SZ) reported first-quarter results, net profit of 43.5628 million yuan, an increase of 31.62% over the previous year
Tonghe Pharmaceutical (300636.SZ) released its report for the first quarter of 2024, with revenue of 206 million yuan, and...
Jiangxi Synergy Pharmaceutical Co., Ltd. (SZSE:300636) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
Jiangxi Synergy Pharmaceutical Co., Ltd. (SZSE:300636) shareholders would be excited to see that the share price has had a great month, posting a 32% gain and recovering from prior weakness. Not al
Pacific Securities: The API industry is in the de-inventory phase or nearing its end, and the 24-year sector is expected to usher in a beta market
The Zhitong Finance App learned that Pacific Securities released a research report saying that in December 2023, production of chemical raw materials by industrial enterprises above the Chinese scale began to resume growth, with a year-on-year increase of 2% and a month-on-month increase of 35%. From January to February 2024, production was 546,000 tons. Although the year-on-year decline was 7.6%, it has already exceeded the same period in 2021 and 2022, continuing the improvement at the end of 2023. As major product patents expire one after another and overseas inventory removal gradually comes to an end, the demand side of the API sector is expected to gradually pick up in 2024, ushering in a beta market. Recommended attention: 1) Continued direction in 2024
Jiangxi Synergy Pharmaceutical Co., Ltd.'s (SZSE:300636) Market Cap Rose CN¥403m Last Week; Retail Investors Who Hold 58% Profited and so Did Insiders
Key Insights The considerable ownership by retail investors in Jiangxi Synergy Pharmaceutical indicates that they collectively have a greater say in management and business strategy The top 25 share
Tonghe Pharmaceutical (300636.SZ): Approved as a high-tech enterprise
On February 23, Gelonghui | Tonghe Pharmaceutical (300636.SZ) announced that the company was recognized as a high-tech enterprise in 2007 and obtained the “High-tech Enterprise Certificate” issued by the relevant departments, and later passed several reviews and re-accreditation. In 2023, the company carried out the high-tech enterprise re-certification process in accordance with relevant regulations, and recently received the “High-tech Enterprise Certificate” jointly issued by the Jiangxi Provincial Department of Science and Technology, the Jiangxi Provincial Department of Finance, and the Jiangxi Provincial Taxation Bureau of the State Administration of Taxation.
Risks Still Elevated At These Prices As Jiangxi Synergy Pharmaceutical Co., Ltd. (SZSE:300636) Shares Dive 28%
To the annoyance of some shareholders, Jiangxi Synergy Pharmaceutical Co., Ltd. (SZSE:300636) shares are down a considerable 28% in the last month, which continues a horrid run for the company. The
Jiangxi Synergy Pharmaceutical Co., Ltd. (SZSE:300636) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Jiangxi Synergy Pharmaceutical (SZSE:300636) has had a rough month with its share price down 18%. But if you pay close attention, you might find that its key financial indicators look quite decent,
Tonghe Pharmaceutical (300636.SZ): The ban on 72.926,200 restricted shares will be lifted on January 29
On January 24, Ge Longhui Pharmaceutical (300636.SZ) announced an indicative announcement on the listing and circulation of restricted shares issued to specific targets. The shares that have been lifted are shares issued by the company to specific targets. The number of shares that have been lifted is 729,261.62 million shares, accounting for 17.23% of the current 423,136,145 shares of the company's total share capital. The stock listing and circulation date for which sales restrictions have been lifted is January 29, 2024 (Monday).
Tonghe Pharmaceutical (300636.SZ): It is likely that in 2024, the company's revenue from new products will surpass mature varieties
Gelonghui January 12 丨 Tonghe Pharmaceutical (300636.SZ) was surveyed by a specific target on January 10, 2024, on “When will the company's revenue from the new product segment surpass mature varieties? What is the outlook for 2024?” The company replied that it is likely that in 2024, the company's revenue from new products will surpass that of mature varieties.
Tonghe Pharmaceutical (300636.SZ): The gross margin of the CDMO business is above 40%
Gelonghui January 12丨Tonghe Pharmaceutical (300636.SZ) was surveyed by a specific target on January 10, 2024, about “How much is the gross margin of the company's CDMO business? What is the outlook for 2024?” The company replied that the gross margin of the company's CDMO business is above 40%; judging from the current market situation, the increase in CDMO business revenue in 2024 is limited.
Tonghe Pharmaceutical (300636.SZ): Gabapentin shipments are expected to increase significantly in 2024 compared to 2023
Gelonghui January 12 丨 Tonghe Pharmaceutical (300636.SZ) was surveyed by a specific target on January 10, 2024, on “How is sales of mature varieties of Gabapentin climbing?” The company replied that there was a marked increase in Gabapentin shipments in the fourth quarter of 2023, but the increase in large orders will have to wait until 2024. It is expected that Gabapentin shipments will increase significantly in 2024 compared to 2023. Our target is 800-1000 tons.
Tonghe Pharmaceutical (300636.SZ): New products have yet to be released in the high-end market in 2023. The growth mainly comes from emerging markets
Gelonghui January 12丨Tonghe Pharmaceutical (300636.SZ) was surveyed by a specific target on January 10, 2024, on “What is the most important source of incremental revenue growth in 2024?” The company replied that the main source of growth is the new product sector. New products have yet to be released in the high-end market in 2023. The growth mainly comes from emerging markets, and sales in emerging markets are greatly affected by customers' ability to pay foreign exchange. It is expected that with the end of the US dollar rate hike, the foreign exchange payment situation in emerging markets will actually improve. In this context, new products achieved sales revenue of 249 million in the first three quarters of 2023, and still
Tonghe Pharmaceutical (300636.SZ): All 4 workshops in the first phase of the second factory area project are in the trial production stage
Gelonghui, January 9 | Tonghe Pharmaceutical (300636.SZ) said at an investor relations event that all 4 workshops in the first phase of the second plant are already in the trial production stage, new products in the high-end market will begin to be released in 2024, and the capacity utilization rate of the first phase of the second plant can reach a high level relatively quickly.
Tonghe Pharmaceutical (300636.SZ): CDMO business revenue in 2023 may be tens of millions lower than the estimated 185 million
Gelonghui, January 9 | Tonghe Pharmaceutical (300636.SZ) said at an investor relations event that the overall economic situation is not very good. In the CDMO business, customers are requesting price cuts and customers are also requesting delays in delivery, so the CDMO business revenue in 2023 may be tens of millions lower than the estimated 185 million yuan. Judging from the current market situation, CDMO business revenue growth in 2024 is also limited.
Tonghe Pharmaceutical (300636.SZ): It is expected that after new product patents expire in the high-end market in 2024, the high-end market will begin to expand
Gelonghui, January 9 | Tonghe Pharmaceutical (300636.SZ) said at an investor relations event that at present, new products have not been released in the high-end market. The growth mainly comes from emerging markets, and sales to emerging markets are greatly affected by customers' ability to pay foreign exchange. It is expected that with the end of the US dollar rate hike, the foreign exchange payment situation in emerging markets will actually improve. Of course, in this context, new products achieved sales revenue of 249 million in the first three quarters of 2023, which is still a year-on-year increase of 71%. It is expected that in 2024, after new product patents expire one after another in the high-end market, the high-end market will begin to expand.
Tonghe Pharmaceutical (300636.SZ): At present, our mature varieties have not been impacted by India
Gelonghui, January 9 | Tonghe Pharmaceutical (300636.SZ) said at an investor relations event that although the addition of India has made competition more intense, we have full confidence in our technology and cost side control. Some of our products are sold directly to local Indian companies, which fully demonstrates Tonghe's cost competitiveness. At present, our mature varieties have not been impacted by India. The decline in orders for mature varieties is mainly due to downstream users going out of inventory, not because competitors have taken orders, but will return to normal.
Tonghe Pharmaceutical (300636.SZ): The company's mature varieties experienced a decline in sales volume and price decline in 2023
Gelonghui, January 9 | Tonghe Pharmaceutical (300636.SZ) said at an investor relations event that the company's mature varieties did experience a decline in sales volume and price drop in 2023. The main reason for the decline in sales was that foreign customers went into inventory. The decline in product prices will have a certain impact on the company's revenue, but since the price of upstream raw materials also declined at the same time, the overall impact on the company's gross margin was not significant.
Tonghe Pharmaceutical (300636.SZ): Gabapentin shipments in the fourth quarter of this year did not reach 250 tons
Glonghui, December 18|Tonghe Pharmaceutical (300636.SZ) was surveyed by specific targets on December 15, 2023. “Can the shipment volume of gabapentin reach 250 tons in the fourth quarter? What is the target for next year's shipment volume?” The company replied that the shipment volume of gabapentin in the fourth quarter of this year did not reach 250 tons. There was already a marked increase in shipments in the fourth quarter, but the increase in large orders will still have to wait until next year. It is expected that the shipment volume of gabapentin in 2024 will increase significantly compared to 2023.
Tonghe Pharmaceutical (300636.SZ): 2023 CDMO business revenue may be lower than the original forecast of 185 million
Gelonghui December 18 | Tonghe Pharmaceutical (300636.SZ) was surveyed by specific targets on December 15, 2023. “The company previously anticipated that the CDMO business would generate 185 million dollars in revenue in 2023. Has anything changed now?” The company replied that the current overall economic situation is not very optimistic. In the CDMO business, there are customer requests that delivery be delayed, so the revenue of the CDMO business in 2023 may be lower than the original estimate of 185 million yuan.
Analysis
Price Target
No Data
